

Diabetes 2030 Forecasts, 2015

DETROIT Metropolitan Area Diabetes Data & Forecasts

Includes: Detroit-Warren-Dearborn, MI Metropolitan Statistical Area

Metro Total Population Forecasts	2015	2020	2025	2030
Entire Population	4,472,900	4,471,200	4,436,900	4,337,100
Prediabetes	1,254,800	1,295,700	1,324,300	1,296,200
Diagnosed diabetes	388,000	459,400	512,600	541,000
Undiagnosed diabetes	134,000	150,600	159,500	159,500
Total with diabetes (diagnosed and undiagnosed)	522,000	610,100	672,000	700,500
Complications:				
Visual impairment	63,600	73,100	79,200	81,100
Renal failure	920	1,060	1,140	1,160
Leg amputations	800	870	900	870
Annual deaths attributable to diabetes	4,180	4,720	5,000	5,000
Total annual cost (2015 dollars)	\$5.4 B	\$6.3 B	\$6.9 B	\$7.2 B
Annual medical costs	\$4.0 B	\$4.7 B	\$5.1 B	\$5.3 B
Annual nonmedical costs	\$1.4 B	\$1.6 B	\$1.8 B	\$1.9 B

Metro Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	647,400	722,100	790,900	845,700
Prediabetes	330,200	368,300	403,400	431,300
Diagnosed diabetes	122,400	136,500	149,500	159,800
Undiagnosed diabetes	45,300	50,500	55,400	59,200
Total with diabetes (diagnosed and undiagnosed)	167,700	187,000	204,800	219,000
Complications:				
Visual impairment	22,900	24,900	26,500	27,700
Renal failure	380	410	430	440
Leg amputations	280	290	290	290
Annual deaths attributable to diabetes	2,880	3,170	3,250	3,150
Total annual cost (2015 dollars)	\$2.1 B	\$2.4 B	\$2.6 B	\$2.8 B
Annual medical costs	\$2.0 B	\$2.2 B	\$2.4 B	\$2.6 B
Annual nonmedical costs	\$0.1 B	\$0.2 B	\$0.2 B	\$0.2 B

These forecasts are based on the latest available national diabetes data, including U.S. Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.